Alx Oncology Holdings (ALXO) Other Non Operating Income (2020 - 2026)
Alx Oncology Holdings recorded quarterly Other Non Operating Income of $188000.0 in Q1 2026, up 1205.88% quarter-over-quarter from -$17000.0 in Q4 2025, and up 1809.09% year-over-year from $9847.6 in Q1 2025.
Alx Oncology Holdings' Other Non Operating Income history runs 7 years deep, the most recent figure standing at $188000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income rose 1809.09% year-over-year to $188000.0; the TTM figure through Mar 2026 stood at $163000.0 (up 1058.82% YoY), while the FY2025 annual figure was -$36000.0, down 80.0% from the prior year.
- Other Non Operating Income came in at $188000.0 for Q1 2026 at Alx Oncology Holdings, up from -$17000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $324000.0 in Q2 2023 to a low of -$29000.0 in Q4 2023.
- A 5-year average of $29352.9 and a median of -$5000.0 in 2022 frame the typical range for Other Non Operating Income.
- Across the five-year window, Other Non Operating Income jumped 6580.0% in 2023 and slumped 1600.0% in 2025, its largest moves.
- Alx Oncology Holdings' Other Non Operating Income stood at -$2000.0 in 2022, then plunged by 1350.0% to -$29000.0 in 2023, then soared by 96.55% to -$1000.0 in 2024, then plunged by 1600.0% to -$17000.0 in 2025, then soared by 1205.88% to $188000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $188000.0, -$17000.0, and -$6000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 188,000.00 |
| Dec 31, 2025 | -17,000.00 |
| Sep 30, 2025 | -6,000.00 |
| Jun 30, 2025 | -2,000.00 |
| Mar 31, 2025 | -11,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Sep 30, 2024 | 3,000.00 |
| Jun 30, 2024 | -8,000.00 |
| Mar 31, 2024 | -14,000.00 |
| Dec 31, 2023 | -29,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Jun 30, 2023 | 324,000.00 |
| Mar 31, 2023 | 95,000.00 |
| Dec 31, 2022 | -2,000.00 |
| Sep 30, 2022 | -7,000.00 |
| Jun 30, 2022 | -5,000.00 |
| Mar 31, 2022 | -8,000.00 |
| Dec 31, 2021 | 5,000.00 |
| Sep 30, 2021 | -12,000.00 |
| Jun 30, 2021 | 2,000.00 |
| Mar 31, 2021 | -2,000.00 |
| Dec 31, 2020 | -600,000.00 |
| Sep 30, 2020 | -111,000.00 |
| Jun 30, 2020 | -305,000.00 |
| Mar 31, 2020 | 7,000.00 |